Its ability to reduce food intake by enhancing satiety further supports individuals in their weight management efforts, a common challenge among those with type 2 diabetes
[1] [2] As an investigational medicinal product (IMP), it does not yet hold a marketing authorisation from the MHRA or EMA, and no product-specific storage data are publicly available
The nausea results from GLP-1 receptor activation in both the gut (slowing gastric emptying) and the brainstem (activating the area postrema)
These pathways connect the nervous system with the hypothalamic-pituitary-gonadal axis, which helps control sex-related and endocrine functions
This could be due to genetic variations, nutrient deficiencies, toxins, infections, and/or the digestive issues often present in those with Hashimotos
Discuss this option with your prescriber, who can evaluate the risk-benefit profile for your specific situation